申请人:Eisai Co., Ltd.
公开号:EP0722936A1
公开(公告)日:1996-07-24
A fused pyridazine compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof which exhibits an inhibitory activity against cyclic GMP phosphodiesterase (hereinafter referred to as "cGMP-PDE").
The compounds are useful as preventive and therapeutic agents for diseases for which a cGMP-PDE inhibiting action is efficacious, for example, ischemic heart diseases such as angina pectoris, myocardial infarct and chronic and acute cardiac failure, pulmonary hypertension, arteriosclerosis and bronchial asthma.
由以下通式(I)代表的融合哒嗪化合物或其药理学上可接受的盐,对环 GMP 磷酸二酯酶(以下简称 "cGMP-PDE")具有抑制活性。
这些化合物可作为 cGMP-PDE 抑制作用有效的疾病的预防和治疗药物,例如缺血性心脏病,如心绞痛、心肌梗塞、慢性和急性心力衰竭、肺动脉高压、动脉硬化和支气管哮喘。